Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India.

Moonan PK, Nair SA, Agarwal R, Chadha VK, Dewan PK, Gupta UD, Ho CS, Holtz TH, Kumar AM, Kumar N, Kumar P, Maloney SA, Mase SR, Oeltmann JE, Paramasivan CN, Parmar MM, Rade KK, Ramachandran R, Rao R, Salhorta VS, Sarin R, Sarin S, Sachdeva KS, Selvaraju S, Singla R, Surie D, Tonsing J, Tripathy SP, Khaparde SD.

BMJ Glob Health. 2018 Oct 8;3(5):e001135. doi: 10.1136/bmjgh-2018-001135. eCollection 2018.

2.

Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysis.

Khaparde S, Raizada N, Nair SA, Denkinger C, Sachdeva KS, Paramasivan CN, Salhotra VS, Vassall A, Hoog AV.

PLoS One. 2017 Sep 7;12(9):e0184270. doi: 10.1371/journal.pone.0184270. eCollection 2017.

3.

Index-TB guidelines: Guidelines on extrapulmonary tuberculosis for India.

Sharma SK, Ryan H, Khaparde S, Sachdeva KS, Singh AD, Mohan A, Sarin R, Paramasivan CN, Kumar P, Nischal N, Khatiwada S, Garner P, Tharyan P.

Indian J Med Res. 2017 Apr;145(4):448-463. doi: 10.4103/ijmr.IJMR_1950_16.

4.

Feasibility and Operational Performance of Tuberculosis Detection by Loop-Mediated Isothermal Amplification Platform in Decentralized Settings: Results from a Multicenter Study.

Gray CM, Katamba A, Narang P, Giraldo J, Zamudio C, Joloba M, Narang R, Paramasivan CN, Hillemann D, Nabeta P, Amisano D, Alland D, Cobelens F, Boehme CC.

J Clin Microbiol. 2016 Aug;54(8):1984-91. doi: 10.1128/JCM.03036-15. Epub 2016 May 18.

5.

Line probe assay: a look at non-interpretable results.

Paramasivan CN, Raizada N.

Int J Tuberc Lung Dis. 2016 Feb;20(2):146. doi: 10.5588/ijtld.15.0982. No abstract available.

PMID:
26792462
6.

Piloting Upfront Xpert MTB/RIF Testing on Various Specimens under Programmatic Conditions for Diagnosis of TB & DR-TB in Paediatric Population.

Raizada N, Sachdeva KS, Swaminathan S, Kulsange S, Khaparde SD, Nair SA, Khanna A, Chopra KK, Hanif M, Sethi GR, Umadevi KR, Keshav Chander G, Saha B, Shah A, Parmar M, Ghediya M, Jaju J, Boehme C, Paramasivan CN.

PLoS One. 2015 Oct 15;10(10):e0140375. doi: 10.1371/journal.pone.0140375. eCollection 2015.

7.

The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant Tuberculosis.

Sachdeva KS, Raizada N, Gupta RS, Nair SA, Denkinger C, Paramasivan CN, Kulsange S, Thakur R, Dewan P, Boehme C, Arinaminpathy N.

PLoS One. 2015 Jul 1;10(7):e0131438. doi: 10.1371/journal.pone.0131438. eCollection 2015.

8.

Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India.

Sachdeva KS, Raizada N, Sreenivas A, Van't Hoog AH, van den Hof S, Dewan PK, Thakur R, Gupta RS, Kulsange S, Vadera B, Babre A, Gray C, Parmar M, Ghedia M, Ramachandran R, Alavadi U, Arinaminpathy N, Denkinger C, Boehme C, Paramasivan CN.

PLoS One. 2015 May 21;10(5):e0126065. doi: 10.1371/journal.pone.0126065. eCollection 2015.

9.

A multi-site validation in India of the line probe assay for the rapid diagnosis of multi-drug resistant tuberculosis directly from sputum specimens.

Raizada N, Sachdeva KS, Chauhan DS, Malhotra B, Reddy K, Dave PV, Mundade Y, Patel P, Ramachandran R, Das R, Solanki R, Wares DF, Sahu S, O'Brien R, Paramasivan CN, Dewan PK.

PLoS One. 2014 Feb 19;9(2):e88626. doi: 10.1371/journal.pone.0088626. eCollection 2014.

10.
11.

Comparative evaluation of GenoType MTBDRplus line probe assay with solid culture method in early diagnosis of multidrug resistant tuberculosis (MDR-TB) at a tertiary care centre in India.

Yadav RN, Singh BK, Sharma SK, Sharma R, Soneja M, Sreenivas V, Myneedu VP, Hanif M, Kumar A, Sachdeva KS, Paramasivan CN, Vollepore B, Thakur R, Raizada N, Arora SK, Sinha S.

PLoS One. 2013 Sep 5;8(9):e72036. doi: 10.1371/journal.pone.0072036. eCollection 2013.

12.

Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.

Jawahar MS, Banurekha VV, Paramasivan CN, Rahman F, Ramachandran R, Venkatesan P, Balasubramanian R, Selvakumar N, Ponnuraja C, Iliayas AS, Gangadevi NP, Raman B, Baskaran D, Kumar SR, Kumar MM, Mohan V, Ganapathy S, Kumar V, Shanmugam G, Charles N, Sakthivel MR, Jagannath K, Chandrasekar C, Parthasarathy RT, Narayanan PR.

PLoS One. 2013 Jul 3;8(7):e67030. doi: 10.1371/journal.pone.0067030. Print 2013.

13.

Contribution of medical colleges to tuberculosis control in India under the Revised National Tuberculosis Control Programme (RNTCP): lessons learnt & challenges ahead.

Sharma SK, Mohan A, Chauhan LS, Narain JP, Kumar P, Behera D, Sachdeva KS, Kumar A; Task Force for Involvement of Medical Colleges in Revised National Tuberculosis Control Programme, Agarwal P, Awadh NT, Bansal A, Baruah S, Baruwa P, Balasangameshwara VH, Balasubramanian R, Bhardwaj AK, Bhargav S, Chadha S, Chaddha VK, Chhatwal M, Da Costa AL, Dash DP, Dep J, Dhingra S, Dhooria Harmeet S, Frieden TR, Garg A, Granich R, Gulati V, Gupta D, Gupta D, Gupta KB, Gupta KN, Jaikishan, Janmeja AK, Jawahar MS, Jethani SL, Jindal SK, John KR, Kalra OP, Kalra VP, Kannan AT, Kayshap S, Keshav Chander G, Khushwa SS, Kushwaha RS, Kumar V, Laskar B, Leela Itty Amma KR, Leuva AT, Maitra Malay K, Mesquita AM, Mathew T, Mundade Y, Munje R, Nagpal S, Nagaraja C, Nair S, Narayanan OR, Paramasivan CN, Parmar M, Prasad R, Phukan AC, Prasanna R, Purty A, Ramachandran R, Ramachandran R, Ravindran C, Reddy Raveendra HR, Sahu S, Santosha, Sarin R, Sarkar S, Sarma KC, Saxena P, Sehgal S, Sharath N, Sharma G, Sharma N, Shridhar PK, Shukla RS, Singh O, Singh NT, Singh V, Singla R, Sinha N, Sinha P, Sinha S, Solanki R, Sreenivas A, Srinath S, Subhakar K, Suri JC, Talukdar P, Tonsing J, Tripathy SP, Vaidyanathan P, Vashist RP, Venu K.

Indian J Med Res. 2013 Feb;137(2):283-94.

14.

Global health: Integrating national laboratory health systems and services in resource-limited settings.

Parsons LM, Somoskovi A, Lee E, Paramasivan CN, Schneidman M, Birx D, Roscigno G, Nkengasong J.

Afr J Lab Med. 2012 Jun 11;1(1):11. doi: 10.4102/ajlm.v1i1.11. eCollection 2012.

15.

Docking studies on novel analogues of 8 methoxy fluoroquinolones against GyrA mutants of Mycobacterium tuberculosis.

Anand RS, Somasundaram S, Doble M, Paramasivan CN.

BMC Struct Biol. 2011 Dec 12;11:47. doi: 10.1186/1472-6807-11-47.

16.

Evaluating PCR, culture & histopathology in the diagnosis of female genital tuberculosis.

Thangappah RB, Paramasivan CN, Narayanan S.

Indian J Med Res. 2011 Jul;134:40-6.

17.

Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities.

Parsons LM, Somoskövi A, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, Spector S, Roscigno G, Nkengasong J.

Clin Microbiol Rev. 2011 Apr;24(2):314-50. doi: 10.1128/CMR.00059-10. Review.

18.

Performance of three LED-based fluorescence microscopy systems for detection of tuberculosis in Uganda.

Albert H, Manabe Y, Lukyamuzi G, Ademun P, Mukkada S, Nyesiga B, Joloba M, Paramasivan CN, Perkins MD.

PLoS One. 2010 Dec 28;5(12):e15206. doi: 10.1371/journal.pone.0015206.

19.

First- and second-line drug resistance patterns among previously treated tuberculosis patients in India.

Paramasivan CN, Rehman F, Wares F, Sundar Mohan N, Sundar S, Devi S, Narayanan PR.

Int J Tuberc Lung Dis. 2010 Feb;14(2):243-6.

PMID:
20074419
20.

Experience establishing tuberculosis laboratory capacity in a developing country setting.

Paramasivan CN, Lee E, Kao K, Mareka M, Kubendiran G, Kumar TA, Keshavjee S, Satti H, Alabi G, Raviglione M, Roscigno G.

Int J Tuberc Lung Dis. 2010 Jan;14(1):59-64.

PMID:
20003696
21.

Surveillance of drug-resistant tuberculosis in the state of Gujarat, India.

Ramachandran R, Nalini S, Chandrasekar V, Dave PV, Sanghvi AS, Wares F, Paramasivan CN, Narayanan PR, Sahu S, Parmar M, Chadha S, Dewan P, Chauhan LS.

Int J Tuberc Lung Dis. 2009 Sep;13(9):1154-60.

PMID:
19723407
22.

Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis.

Sulochana S, Mitchison DA, Kubendiren G, Venkatesan P, Paramasivan CN.

J Chemother. 2009 Apr;21(2):127-34.

PMID:
19423464
23.

Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance.

Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, Hoffner S, Drobniewski F, Barrera L, van Soolingen D, Boulabhal F, Paramasivan CN, Kam KM, Mitarai S, Nunn P, Raviglione M; Global Project on Anti-Tuberculosis Drug Resistance Surveillance.

Lancet. 2009 May 30;373(9678):1861-73. doi: 10.1016/S0140-6736(09)60331-7. Epub 2009 Apr 15. Review.

24.

Simple direct drug susceptibility tests on sputum samples for early detection of resistance in tubercle bacilli.

Mathew S, Nalini SM, Rahman F, Dastageer A, Sundaram V, Paramasivan CN.

Indian J Tuberc. 2007 Oct;54(4):184-9.

PMID:
18072531
25.

Localized Pulmonary Mycobacterium avium Disease in HIV-Infected Patients Without Access to HAART.

Swaminathan S, Padmapriyadarsini C, Ramachandran R, Menon PA, Mohan NS, Kubendiran G, Paramasivan CN.

J Int Assoc Physicians AIDS Care (Chic). 2007 Dec;6(4):264-8. Epub 2007 Sep 14. No abstract available.

PMID:
17873247
26.

Nocardia bacteraemia in an HIV positive patient - a case report.

Ramchandran R, Swaminathan S, Sulochana S, Paramasivan CN.

Indian J Med Microbiol. 2003 Oct-Dec;21(4):287-8.

27.

Cutaneous tuberculosis.

Umapathy KC, Begum R, Ravichandran G, Rehman F, Paramasivan CN, Ramanathan VD.

Trop Med Int Health. 2007 Jul;12(7):902. No abstract available.

28.

Analysis of fluoroquinolone resistance in clinical isolates of Mycobacterium tuberculosis from India.

Sulochana S, Narayanan S, Paramasivan CN, Suganthi C, Narayanan PR.

J Chemother. 2007 Apr;19(2):166-71.

PMID:
17434825
29.

Surveillance of anti-tuberculosis drug resistance in Ernakulam District, Kerala State, South India.

Joseph MR, Shoby CT, Amma GR, Chauhan LS, Paramasivan CN.

Int J Tuberc Lung Dis. 2007 Apr;11(4):443-9.

PMID:
17394692
30.

Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.

Kubendiran G, Paramasivan CN, Sulochana S, Mitchison DA.

J Chemother. 2006 Dec;18(6):617-23.

PMID:
17267339
31.

National anti-tuberculosis drug resistance survey, 2002, in Myanmar.

Ti T, Lwin T, Mar TT, Maung W, Noe P, Htun A, Kluge HH, Wright A, Aziz MA, Paramasivan CN.

Int J Tuberc Lung Dis. 2006 Oct;10(10):1111-6.

PMID:
17044203
32.

Comprehensive findings on clinical, bacteriological, histopathological and therapeutic aspects of cutaneous tuberculosis.

Umapathy KC, Begum R, Ravichandran G, Rahman F, Paramasivan CN, Ramanathan VD.

Trop Med Int Health. 2006 Oct;11(10):1521-8.

33.

Initial drug susceptibility profile of M. tuberculosis among patients under TB programme in South India.

Santha T, Thomas A, Chandrasekaran V, Selvakumar N, Gopi PG, Subramani R, Rajeswari R, Rani B, Paramasivan CN, Perumal M, Wares F, Narayanan PR.

Int J Tuberc Lung Dis. 2006 Jan;10(1):52-7.

PMID:
16466037
34.

Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.

Jawahar MS, Rajaram K, Sivasubramanian S, Paramasivan CN, Chandrasekar K, Kamaludeen MN, Thirithuvathas AJ, Ananthalakshmi V, Prabhakar R.

Trop Med Int Health. 2005 Nov;10(11):1090-8.

35.

Anti-tuberculosis drug resistance in patients with HIV and tuberculosis in South India.

Swaminathan S, Paramasivan CN, Ponnuraja C, Iliayas S, Rajasekaran S, Narayanan PR.

Int J Tuberc Lung Dis. 2005 Aug;9(8):896-900.

PMID:
16104637
36.

Requirement of the mymA operon for appropriate cell wall ultrastructure and persistence of Mycobacterium tuberculosis in the spleens of guinea pigs.

Singh A, Gupta R, Vishwakarma RA, Narayanan PR, Paramasivan CN, Ramanathan VD, Tyagi AK.

J Bacteriol. 2005 Jun;187(12):4173-86.

37.

In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.

Sulochana S, Rahman F, Paramasivan CN.

J Chemother. 2005 Apr;17(2):169-73.

PMID:
15920901
38.

Increased expression of Mycobacterium tuberculosis 19 kDa lipoprotein obliterates the protective efficacy of BCG by polarizing host immune responses to the Th2 subtype.

Rao V, Dhar N, Shakila H, Singh R, Khera A, Jain R, Naseema M, Paramasivan CN, Narayanan PR, Ramanathan VD, Tyagi AK.

Scand J Immunol. 2005 May;61(5):410-7.

39.

Computerized tomography detects pulmonary lesions in children with normal radiographs diagnosed to have tuberculosis.

Swaminathan S, Raghavan A, Datta M, Paramasivan CN, Saravanan KC.

Indian Pediatr. 2005 Mar;42(3):258-61.

40.

Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.

Paramasivan CN, Sulochana S, Kubendiran G, Venkatesan P, Mitchison DA.

Antimicrob Agents Chemother. 2005 Feb;49(2):627-31.

41.

Two speedier phenotypic methods on drug susceptibility testing of Mycobacterium tuberculosis.

Paramasivan CN.

Indian J Med Res. 2004 Nov;120(5):440-1. No abstract available.

PMID:
15591627
42.

Drug resistance in tuberculosis in India.

Paramasivan CN, Venkataraman P.

Indian J Med Res. 2004 Oct;120(4):377-86. Review.

PMID:
15520487
43.

Unrecognised tuberculosis in HIV-infected patients: sputum culture is a useful tool.

Swaminathan S, Paramasivan CN, Kumar SR, Mohan V, Venkatesan P.

Int J Tuberc Lung Dis. 2004 Jul;8(7):896-8.

PMID:
15260283
44.

Evaluation of microplate Alamar blue assay for drug susceptibility testing of Mycobacterium avium complex isolates.

Vanitha JD, Paramasivan CN.

Diagn Microbiol Infect Dis. 2004 Jul;49(3):179-82.

PMID:
15246507
45.

Seroprevalence of human immunodeficiency virus (HIV) infection among tuberculosis patients in Tamil Nadu.

Ramachandran R, Datta M, Subramani R, Baskaran G, Paramasivan CN, Swaminathan S.

Indian J Med Res. 2003 Oct;118:147-51.

PMID:
14700348
46.

Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs.

Singh R, Rao V, Shakila H, Gupta R, Khera A, Dhar N, Singh A, Koul A, Singh Y, Naseema M, Narayanan PR, Paramasivan CN, Ramanathan VD, Tyagi AK.

Mol Microbiol. 2003 Nov;50(3):751-62.

47.

Status of drug resistance in tuberculosis after the introduction of rifampicin in India.

Paramasivan CN.

J Indian Med Assoc. 2003 Mar;101(3):154-6.

PMID:
14603961
48.

Large-restriction-fragment polymorphism analysis of Mycobacterium chelonae and Mycobacterium terrae isolates.

Vanitha JD, Venkatasubramani R, Dharmalingam K, Paramasivan CN.

Appl Environ Microbiol. 2003 Jul;69(7):4337-41.

49.

Quality assurance studies in eight State tuberculosis laboratories in India.

Paramasivan CN, Venkataraman P, Vasanthan JS, Rahman F, Narayanan PR.

Int J Tuberc Lung Dis. 2003 Jun;7(6):522-7.

PMID:
12797693
50.

Surveillance of drug resistance in tuberculosis in two districts of South India.

Paramasivan CN, Venkataraman P, Chandrasekaran V, Bhat S, Narayanan PR.

Int J Tuberc Lung Dis. 2002 Jun;6(6):479-84.

PMID:
12068979

Supplemental Content

Loading ...
Support Center